Immunic Inc. (NASDAQ:IMUX) does about 1.05M shares in volume on a normal day but saw 679992 shares change hands in Friday trading. The company now has a market cap of 88.68M USD. Its current market price is $2.01, marking an increase of 1.52% compared to the previous close of $1.98. The 52 week high reached by this stock is $13.39 whilst the lowest price level in 52 weeks is $1.11. The script in recent trading has seen the stock touch a high of $2.07 and a low of $1.95.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Immunic Inc. (IMUX) has a 20-day trading average at $2.20 and the current price is -84.99% off the 52-week high compared with 81.08% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.69 and its 200-day simple moving average is $3.47. If we look at the stock’s price movements over the week, volatility stands at 7.86%, which increases to 11.97% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 49.42 to suggest the stock is neutral.
4 analysts observing the Immunic Inc. (IMUX) stock have set the 12-month price targets for the company’s shares at between $5.00 and $39.00. The consensus objective for the share price is $20.83, suggesting that the stock has a potential upside of 90.35% over the period. The median price target is 79.9% away from the current levels at $10.00.
FactSet Research has provided data showing that 4 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on October 21, 2022 when SVB Leerink downgraded the stock to “Mkt Perform” and issued a price target of $5. Aegis Capital initiated its price target at $55.
The current price level is -8.24%, 19.76%, and -42.42% away from its SMA20, SMA50, and SMA200 respectively, with the IMUX price moving below the 50-day SMA on February 17. Immunic Inc. (IMUX) stock is down -1.47% over the week and 12.29% over the past month. Its price is 43.57% year-to-date and -84.85% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.69 below consensus estimates by -$0.03. The company’s next earnings report is expected on 05/11/2023, with forecasts estimating quarterly EPS at -$0.73 and -$2.9 for whole year. IMUX’s earnings per share are forecast to grow by 26.20% this year and 27.60% over next year.
Its 12-month price target is $10.00. To reach the target analysts have set, the stock logically needs to grow 90.35 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $5.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $39.00.
Outstanding shares total 44.36M with insiders holding 18.44% of the shares and institutional holders owning 56.10% of the company’s common stock. The company has a return on equity of -67.90%. The beta has a value of 1.82. Price to book ratio is 0.56.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has added its position in Immunic Inc. (IMUX) to 854,974 shares, mirroring a recent increase by 20.41%. Vanguard Total Stock Market Index added 0.14 million shares of Immunic Inc. common stock bringing its total worth to about $2.05 million at the end of recent close, SEC documents show. Fidelity Extended Market Index Fu cut their holdings by -0.41% in the company over the course of the most recent quarter. It now holds a 0.32% position in Immunic Inc. thanks to 0.14 million shares amounting to $0.34 million.